Therapeutic efficacy of thiocolchicoside-nonsteroidal anti-inflammatory drug combination in pain management: A systematic review and cross-sectional real-world study.
Arnab Karmakar, Akash Jaiswal, Soham Mandal, Afroz Ahmed Khan, Monjori Mitra
{"title":"Therapeutic efficacy of thiocolchicoside-nonsteroidal anti-inflammatory drug combination in pain management: A systematic review and cross-sectional real-world study.","authors":"Arnab Karmakar, Akash Jaiswal, Soham Mandal, Afroz Ahmed Khan, Monjori Mitra","doi":"10.5312/wjo.v16.i8.106769","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Thiocolchicoside (TCC), a muscle relaxant with anti-inflammatory properties, is often used alongside nonsteroidal anti-inflammatory drugs (NSAIDs) to treat musculoskeletal pain. This synergistic approach leverages the complementary mechanisms of action, providing more effective relief for conditions such as arthritis, muscle spasms, and soft tissue injuries.</p><p><strong>Aim: </strong>To evaluate the comparative efficacy of the combination therapy of TCC and NSAIDs <i>vs</i> NSAID monotherapy in pain management.</p><p><strong>Methods: </strong>A systematic search of PubMed and Google Scholar databases through October 2024 was performed to evaluate the effectiveness of combined TCC and NSAID therapy <i>vs</i> NSAIDs alone. A retrospective analysis of electronic medical records from India spanning 3 years (2020-2023) examined treatment patterns and focused on clinical outcomes including pain relief, functional improvement, and adverse effects. Key metrics for assessment included visual analog scale scores and hand-to-floor distance, with secondary outcomes assessing patient satisfaction and adverse event (AE) incidence.</p><p><strong>Results: </strong>A systematic literature search revealed seven studies, involving 1137 subjects, aligning with the eligibility criteria from a total of 833 hits. Combination therapy using parenteral TCC with NSAIDs significantly reduced pain intensity [standardised mean difference (SMD): -1.33, <i>P</i> < 0.001] and enhanced functional improvement (SMD: -1.08, <i>P</i> < 0.001) compared to NSAIDs alone. Patients on combination therapy are 6.7 times more likely to experience over 30% pain relief and 5.2 times more likely to achieve over 50% pain relief. Post surgery pain reduction and patient satisfaction were notably higher in the combination group [odds ratio (OR) = 10.14, <i>P</i> < 0.001]. There were no significant differences in mild/moderate AE rates between the groups (OR = 1.30, <i>P</i> = 0.378).</p><p><strong>Conclusion: </strong>Evidence indicates that multimodal therapy, including parenteral TCC with NSAIDs, provides quicker and effective pain relief, reduces muscle spasms, and improves hand-to-floor distance compared to using NSAIDs or TCC alone.</p>","PeriodicalId":47843,"journal":{"name":"World Journal of Orthopedics","volume":"16 8","pages":"106769"},"PeriodicalIF":2.3000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362649/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Orthopedics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5312/wjo.v16.i8.106769","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Thiocolchicoside (TCC), a muscle relaxant with anti-inflammatory properties, is often used alongside nonsteroidal anti-inflammatory drugs (NSAIDs) to treat musculoskeletal pain. This synergistic approach leverages the complementary mechanisms of action, providing more effective relief for conditions such as arthritis, muscle spasms, and soft tissue injuries.
Aim: To evaluate the comparative efficacy of the combination therapy of TCC and NSAIDs vs NSAID monotherapy in pain management.
Methods: A systematic search of PubMed and Google Scholar databases through October 2024 was performed to evaluate the effectiveness of combined TCC and NSAID therapy vs NSAIDs alone. A retrospective analysis of electronic medical records from India spanning 3 years (2020-2023) examined treatment patterns and focused on clinical outcomes including pain relief, functional improvement, and adverse effects. Key metrics for assessment included visual analog scale scores and hand-to-floor distance, with secondary outcomes assessing patient satisfaction and adverse event (AE) incidence.
Results: A systematic literature search revealed seven studies, involving 1137 subjects, aligning with the eligibility criteria from a total of 833 hits. Combination therapy using parenteral TCC with NSAIDs significantly reduced pain intensity [standardised mean difference (SMD): -1.33, P < 0.001] and enhanced functional improvement (SMD: -1.08, P < 0.001) compared to NSAIDs alone. Patients on combination therapy are 6.7 times more likely to experience over 30% pain relief and 5.2 times more likely to achieve over 50% pain relief. Post surgery pain reduction and patient satisfaction were notably higher in the combination group [odds ratio (OR) = 10.14, P < 0.001]. There were no significant differences in mild/moderate AE rates between the groups (OR = 1.30, P = 0.378).
Conclusion: Evidence indicates that multimodal therapy, including parenteral TCC with NSAIDs, provides quicker and effective pain relief, reduces muscle spasms, and improves hand-to-floor distance compared to using NSAIDs or TCC alone.
背景:硫代秋糖苷(TCC)是一种具有抗炎特性的肌肉松弛剂,常与非甾体抗炎药(NSAIDs)一起用于治疗肌肉骨骼疼痛。这种协同方法利用了互补的作用机制,为关节炎、肌肉痉挛和软组织损伤等疾病提供了更有效的缓解。目的:评价TCC联合非甾体抗炎药与非甾体抗炎药单药治疗疼痛的比较疗效。方法:系统检索PubMed和谷歌Scholar数据库至2024年10月,评估TCC联合非甾体抗炎药治疗与单用非甾体抗炎药治疗的有效性。对印度3年(2020-2023年)电子医疗记录的回顾性分析检查了治疗模式,并重点关注临床结果,包括疼痛缓解、功能改善和不良反应。评估的关键指标包括视觉模拟量表得分和手到地板的距离,次要结果评估患者满意度和不良事件(AE)发生率。结果:系统的文献检索显示了7项研究,涉及1137名受试者,符合833个命中的合格标准。与单用非甾体抗炎药相比,肠外TCC联合非甾体抗炎药显著降低疼痛强度[标准化平均差(SMD): -1.33, P < 0.001],增强功能改善(SMD: -1.08, P < 0.001)。接受联合治疗的患者有6.7倍的可能性体验到30%以上的疼痛缓解,5.2倍的可能性达到50%以上的疼痛缓解。联合用药组术后疼痛减轻率和患者满意度均显著高于对照组[比值比(OR) = 10.14, P < 0.001]。两组间轻、中度AE发生率差异无统计学意义(OR = 1.30, P = 0.378)。结论:有证据表明,与单独使用非甾体抗炎药或TCC相比,包括非甾体抗炎药外注射TCC在内的多模式治疗可以更快有效地缓解疼痛,减少肌肉痉挛,并改善手到地板的距离。